BioSpace News Archive

Immuron Limited is pleased to announce that Ateria Health Australia Pty Ltd, a subsidiary of Ateria Health Limited, has launched Juvia™ in Australia.

Rockwell Medical, Inc. announced that the Company acquired the hemodialysis concentrates business from Evoqua Water Technologies for $11 million up front in cash plus two milestone payments of $2.5 million each at 12- and 24-months from the closing of the transaction.

Vivani Medical, Inc. announced that its wholly-owned subsidiary Cortigent, Inc., a company pioneering neurostimulation to recover critical body function, has completed the fifth year of its Early Feasibility Study of profoundly blind patients implanted with the Orion® Visual Cortical Prosthesis System.

Alzheon, Inc. announced that it will be presenting baseline imaging characteristics from its ongoing APOLLOE4 Phase 3 clinical trial and new correlation analyses from the Phase 2 biomarker study evaluating ALZ-801 oral tablet at the upcoming Alzheimer’s Association International Conference, to be held from July 16 – 20, 2023 in Amsterdam, Netherlands.

NanoViricides, Inc., a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported on the strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV.

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”) is pleased to announce the appointment of Christopher Bull to the board of directors of the Company effective immediately.

Labcorp today announced that it has entered into an agreement with Legacy Health to acquire select assets of its outreach laboratory business, including laboratory facilities and equipment.

Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products.

Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announces the launch of state-of-the-art flow cytometry clinical trial services.

Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human single ascending dose clinical study of RLYB116 has been accepted for presentation as a poster at the 29th International Complement Workshop (ICW), which will take place in Newcastle, UK from August 31 - September 5.